High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience (Q64382180)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

1 reference

lymphoblastic leukemia

1 reference

R E Harris

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

H N Sather

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

S A Feig

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

English

0 references

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

published in

Pediatric Blood Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

233-239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Comparison of Autologous and Allogeneic Bone Marrow Transplantation in Children with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Which treatment for childhood acute lymphoblastic leukaemia in second remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report fro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199804%2930%3A4%3C233%3A%3AAID-MPO5%3E3.0.CO%3B2-H

10.1002/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9473758%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference